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ABSTRACT 1 
Objective: Claudication is the most common manifestation of peripheral arterial disease, 2 
producing significant ambulatory compromise.The purpose of our study was to evaluate patients 3 
with bilateral lower limb claudication and characterize their gait abnormality based on advanced 4 
biomechanical analysis using joint torques and powers. 5 
Methods: Twenty patients with bilateral claudication (40 limbs) and eleven healthy matched 6 
controls (22 limbs) ambulated on a walkway while three dimensional biomechanical data were 7 
collected. Patients walked before and after onset of claudication pain. Joint torques and powers at 8 
early-, mid-, and late-stance for the hip, knee and ankle joints were calculated for claudicating 9 
patients before and after the onset of claudication pain, and were compared to healthy controls.  10 
Results: Claudicating patients exhibited significantly reduced hip and knee power at early-stance 11 
due to decreased torques produced by the hip and knee extensors. In mid-stance, patients had 12 
significantly reduced knee power due to the decreased torques produced by the knee extensors. 13 
In late-stance, reduced propulsion was noted with significant reduction in ankle plantar flexor 14 
torques and power. All differences were present before the onset of pain with worsening of 15 
specific parameters after the onset of pain. 16 
Conclusions: Advanced biomechanical analysis demonstrates that the gait of claudicating 17 
patients is abnormal at baseline in the absence of pain and worsens after onset of pain. Gait of 18 
claudication is characterized by failure of specific and identifiable muscle groups needed to 19 
perform normal walking (weight acceptance, transfer and propulsion). 20 
 21 
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ABSTRACT 1 
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due to decreased torques produced by the hip and knee extensors. In mid-stance, patients had 12 
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In late-stance, reduced propulsion was noted with significant reduction in ankle plantar flexor 14 
torques and power. All differences were present before the onset of pain with worsening of 15 
specific parameters after the onset of pain. 16 
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patients is abnormal at baseline in the absence of pain and worsens after onset of pain. Gait of 18 
claudication is characterized by failure of specific and identifiable muscle groups needed to 19 
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 1 
INTRODUCTION 2 
Intermittent claudication is the most common clinical manifestation of peripheral arterial 3 
disease (PAD) presenting as exercise induced leg muscle pain and gait dysfunction. Claudication 4 
and its associated ambulatory impairment produce impaired quality of life1-3, physical 5 
dependence and poor health outcomes4. Previous work suggests that PAD patients walk slower 6 
with decreased cadence, increased stance time, shorter stride length and a narrower step width as 7 
compared with healthy controls4, 5. However, these changes alone are unable to describe in 8 
sufficient detail the locomotor impairments of claudicating patients and aid in our understanding 9 
of its underlying pathophysiology.  10 
A more detailed quantitative evaluation of gait can be obtained using advanced 11 
biomechanical analysis including joint torques and powers6. Although muscles produce linear 12 
forces, motions at joints are all rotary. The rotary torque is a measure of the tendency of a force 13 
to rotate the limb around a joint and is calculated as the product of the muscle force and the 14 
distance from the joint center that the force is being applied. The net muscle torque does not 15 
represent any one particular muscle but rather describes the net activity of all the muscles acting 16 
across a joint. Joint power can be defined as the rate of work produced by muscles contracting to 17 
move a joint and is determined as the product of the net torque (moment) of the muscles acting 18 
across a joint and the resulting angular velocity of the joint. Joint powers have been used 19 
extensively to identify the mechanisms responsible for pathological gait (in populations such as 20 
elderly, patients with knee and hip arthritis and arthroplasty, anterior cruciate ligament 21 
reconstruction and below knee amputees) and to assess and guide successful rehabilitation 22 
strategies6-8. Similar insights can be gained from patients with PAD utilizing this approach.  23 
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Previous studies of claudicating PAD patients from our laboratory utilizing basic 1 
biomechanical analysis9-11 suggested a potential weakness of the posterior compartment muscles 2 
of the hip and calf as key components of PAD gait impairment. The purpose of the current study 3 
is to utilize joint torques and powers to isolate and identify the individual muscle compartments 4 
responsible for the gait impairment of claudicating patients.  5 
METHODS  6 
Key events during gait stance 7 
The gait cycle (from heel touchdown to heel touchdown) consists of a stance and a swing 8 
period. The stance phase is the most important segment of the gait cycle because during it the 9 
ambulating limb accepts, supports and propels the weight of the body. Furthermore, it is the only 10 
portion of the gait cycle that can be accurately evaluated for joint moments and powers.  The 11 
stance segment can be divided in three distinct phases including the weight acceptance, the 12 
single limb support and the propulsion phases (Figure 1).  13 
INSERT FIGURE 1 ABOUT HERE  14 
Subject inclusion and exclusion criteria  15 
Twenty patients (age: 64.25r9.01 years, body mass: 79.52r13.83 kg; body height: 16 
1.72r0.04 m) diagnosed with moderate arterial occlusive disease and bilateral claudication were 17 
recruited from the vascular surgery clinics of the VA Nebraska and Western Iowa and University 18 
of Nebraska Medical Centers and signed an inform consent prior their participation to the study 19 
that was approved by the institutional review boards of each respective institution. In addition, 20 
eleven gender, age, body-mass, height matched healthy controls (age: 66.27r9.22 years, body 21 
mass: 77.89r10.65 kg, body height: 1.74r0.08 m) were recruited. Patients and controls were 22 
screened and evaluated by two board certified vascular surgeons. Those PAD patients with 23 
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ambulation limiting cardiac, pulmonary, neuromuscular or musculoskeletal disease or those who 1 
experienced pain or discomfort during walking for any reason other than claudication (i.e. 2 
arthritis, low back pain, musculoskeletal problems, and neuropathy) were excluded.  Patient 3 
evaluation included resting ankle brachial index (ABI; a measurement below 0.90 was present in 4 
all subjects with claudication), detailed history, physical exam and direct assessment/observation 5 
of the patient’s walking impairment. A vascular surgeon observed the patient walking and 6 
recorded all symptoms and signs affecting ambulation to insure limitation was secondary to 7 
claudication pain. Control subjects had a resting ABI greater than 0.90 and no subjective or 8 
objective ambulatory dysfunction. Controls were screened in a similar fashion as PAD patients 9 
and were excluded for the same ambulation limiting problems or if pain was experienced during 10 
walking. Informed consent was obtained from all subjects prior to data collection according to 11 
the guidelines of the Institutional Review Boards of the two medical centers. The gait of all 12 
recruited participants was tested in the Biomechanics Laboratory of the University of Nebraska 13 
at Omaha. 14 
Experimental Procedure and Data Collection  15 
Prior to data collection, reflective markers were placed at specific anatomical locations of 16 
each subject’s lower limb utilizing the modified Helen Hayes marker set10. Each subject was 17 
directed to walk using their self-selected pace over a ten meters pathway, while three-18 
dimensional marker trajectories (kinematics) and ground reaction forces (kinetics) were 19 
simultaneously collected. The marker trajectories were captured with an eight high-speed real-20 
time camera system (EvaRT 5.0, Motion Analysis Corp., Santa Rosa, CA) sampling at 60Hz. 21 
The ground reaction force data were acquired with a Kistler force platform sampling at 600 Hz. 22 
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Each patient was tested before (“Pain Free” condition) and after (“Pain” condition) the 1 
onset of claudication pain. During “Pain Free” testing, mandatory rest occurred between the 2 
walking trials to insure that all trials were in a “Pain Free” condition. Once patients completed all 3 
“Pain Free” trials, “Pain” trials were performed.  In order to accomplish this, each patient was 4 
asked to walk on an inclined treadmill with 10% grade at a speed of 0.67m/s-112 until 5 
claudication pain was established. The patients were then immediately removed from the 6 
treadmill and returned to the collection walk-way to acquire the data for the “Pain” condition 7 
without the mandatory resting periods. Controls completed only the “Pain Free” condition trials. 8 
A total of five walking trials were collected from each leg of the subjects for each condition.  9 
Data Analysis  10 
Joint kinetics and kinematics were calculated for the sagittal plane during the stance 11 
phase of walking. An inverse dynamic solution was performed to calculate joint muscle torques 12 
and powers from the joint kinetics and kinematics6. Joint muscle power (Pj) is calculated as the 13 
product of the net torque of force at a joint (Mj) and the relative joint angular velocity (ωj) or 14 
Pj=Mj x ωj (Joules*sec-1 or Watts). Power combines both kinetic (forces) and kinematic (angles 15 
and velocities) information and can be expressed positively or negatively. Positive power 16 
indicates that energy is being generated and negative power that energy is being absorbed by the 17 
muscle group under study. Thus, positive joint muscle power is associated with concentric 18 
muscular contractions, while negative power is associated with eccentric muscular contractions 6. 19 
Joint torques and joint muscle powers were normalized with respect to the subject’s body mass 20 
and expressed as a percentage of the stance phase.  All normalizations occurred after the discrete 21 
points were determined to ensure that the normalization did not distort these values. The peak 22 
values for extensor and flexor torques were identified for the ankle, knee and hip joints (Figure 23 
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2) 6. The variables identified for the ankle were the ankle dorsiflexor torque (ADT) in early 1 
stance and the ankle plantar flexor torque (APT) in late stance; for the knee were the knee 2 
extensor torque (KET) in early stance and the knee flexor torque (KFT) in late stance; for the hip 3 
were the hip extensor torque (HET) in early stance and the hip flexor torque (HFT) in late stance. 4 
In addition, the peak values for power absorption (eccentric contraction) and generation 5 
(concentric contraction) were identified for the ankle, knee and hip joints (Figure 3) 6. The power 6 
variables indentified for the ankle were the power absorption in early (A1) and mid (A2) stance 7 
(correspond to eccentric contraction of the ankle dorsiflexor group) and the power generation in 8 
late stance (A3); for the knee were the power absorption in early stance (K1), the power 9 
generation in the early part of mid-stance (K2), and the knee power absorption in late stance 10 
(K3); for the hip joint were the power generation in early stance (H1), the power absorption in 11 
mid-stance (H2) and the power generation in late stance (H3) 6. Custom made Matlab (Matlab 12 
2007, Mathworks, Inc., Concord, MA) software was used to calculate the joint torques and 13 
powers.  14 
Statistical Analysis 15 
Group means of the peak joint torques and powers were calculated for each testing 16 
condition (“Pain Free” and “Pain” conditions) by combining all legs of each group. Thus, an N 17 
of 40 limbs was generated for the claudicating group and an N of 22 limbs for the control healthy 18 
group. Paired t-tests were used to detect the effects of induced claudication pain, and 19 
independent t-tests were used to examine group effects for each dependent variable using SPSS 20 
(Base 12.0, SPSS Inc., Chicago, IL) software package and parametric statistics13. 21 
RESULTS 22 
Time – distance gait measurements 23 
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 The baseline clinical characteristics of patients and healthy controls are presented in 1 
Table 1. No significant differences were found between groups regarding age, body mass and 2 
body height. When compared to controls, patients had significantly decreased gait velocity, 3 
stride length, cadence and step length in the “Pain Free” condition (Table 2). The differences for 4 
these parameters were further amplified when the patients walked experiencing muscle pain in 5 
the “Pain” condition, with the addition of a significant difference for the duration of the double 6 
support phase (Table 2). Comparing gait time – distance gait measurements before and after 7 
onset of claudication, there was a significant decrease in gait velocity, stride length and step 8 
length and a significant increase in double support phase (Table 2). 9 
INSERT TABLE 1 AND TABLE 2 ABOUT HERE  10 
Weight Acceptance Phase  11 
In comparison to the controls (Tables 3, 4;Figures 2, 3), patients in the “Pain Free” 12 
condition generated significantly decreased torque by the hip extensors (HET) and by the knee 13 
extensors (KET) which translated to significantly decreased power at the hip (H1, reduced 14 
concentric contraction of the hip extensors) and at the knee (K1, reduced eccentric contraction of 15 
the knee extensors). Decreased (although not significant) torque was also produced by the ankle 16 
dorsiflexors (ADT) leading to decreased power absorption at the ankle (A1, reduced eccentric 17 
contraction of the ankle dorsiflexors). In the “Pain” condition, the results for the same parameters 18 
remained significantly different compared to healthy controls (Table 3;Figure 2) while they 19 
became significantly augmented at the knee and ankle level compared to the “Pain Free” 20 
condition. 21 
INSERT TABLE 3 AND TABLE 4 ABOUT HERE  22 
Single Limb Support or Mid-Stance Phase (all the body weight on one limb)  23 
9 
 
In comparison to the controls (Table 3;Figure 2), patients in both conditions generated 1 
significantly decreased knee torque by the knee extensors (KET) which then translated to 2 
significantly decreased knee joint power generation in the early part of mid-stance phase (K2, 3 
reduced concentric contraction of the knee extensors).  4 
Propulsion or Late-Stance Phase 5 
 In comparison to the controls (Table 3;Figure 2), patients in the “Pain Free” condition 6 
produced significantly less power at the ankle (A3, reduced concentric contraction of the ankle 7 
plantarflexors). Once in the “Pain” condition, patients generated significantly decreased ankle 8 
plantarflexor torque (APT) compared to controls and the “Pain Free” condition. This significant 9 
decrease in torque (reduced concentric contraction of the ankle plantar flexors) translated into 10 
further decrease of power generation at the ankle (A3).  11 
INSERT FIGURE 2 AND FIGURE 3 ABOUT HERE  12 
DISCUSSION    13 
The purpose of this study was to utilize joint torques and powers in order to characterize 14 
and provide an in depth understanding of the gait impairment of claudicating patients. Joint 15 
torques and powers were measured while patients walked both with and without claudication 16 
pain and were compared to those of gender-, height-, mass-, and age-matched healthy controls. 17 
Our results from the time-distance gait parameters demonstrate that the character of the PAD gait 18 
appears overall ‘‘sluggish and tired’’.  Patients with claudication have decreased gait velocity, 19 
stride length, cadence and step length and spend more time in the double stance (both limbs on 20 
the ground). These findings are in agreement with previous studies and unequivocally document 21 
the abnormal temporal and spatial gait parameters of claudicating PAD patients4, 5. Utilizing 22 
advanced biomechanical analysis in the form of joint torques and powers, we were able to isolate 23 
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and describe the specific muscle group impairments that operate to produce the gait deficit in 1 
claudicating patients.  Our data demonstrate a decreased ability of the knee and hip extensors to 2 
control weight acceptance and ankle dorsiflexors to eccentrically control the lowering of the foot 3 
to the ground after heel strike in early stance. In mid stance we found a decreased ability of the 4 
knee extensors to concentrically extend the knee in preparation for the single support phase. 5 
Finally, in late stance we demonstrated a decreased ability of the ankle plantarflexors to 6 
concentrically propel the body forward.    7 
Decreased weight acceptance 8 
Trunk support in early stance is provided by the hip extensors concentrically contracting 9 
to extend the hip (H1), the knee extensors eccentrically contracting to allow the knee to flex (K1) 10 
and the ankle dorsiflexors which eccentrically control the movement of the foot towards full 11 
contact with the ground (A1)14. Our findings in PAD patients demonstrate that all three muscle 12 
groups involved in the weight acceptance phase produce less power than in controls both in the 13 
“Pain Free” and the “Pain” conditions. Specifically PAD patients have decreased power 14 
generation by the hip extensors (Gluteus muscles, H1;Figure 2) and the knee extensors 15 
(quadriceps) in early stance (K1;Figure 2) which appear unable to optimally support the body 16 
weight. These power results are supported by our joint torque findings which showed 17 
significantly decreased torque development by the hip (HET) and knee (KET) extensors10. The 18 
demonstrated weakness of the hip and knee extensors in early stance is present before and 19 
becomes worse after the onset of claudication symptoms resulting in diminished ability for 20 
weight acceptance and control of forward momentum when a claudicating patient walks. The 21 
demonstrated weakness of the ankle dorsiflexors in early stance is in agreement with findings our 22 
group has previously published showing that PAD patients have a “foot drop” upon heel strike9.  23 
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Decreased weight support during the mid-stance phase 1 
In the early part of the mid-stance phase the knee extensors concentrically contract to 2 
extend the knee joint in preparation for single leg support. To maintain the energy required for 3 
walking15, it is necessary to “straighten” the leg and maximize the ability to generate potential 4 
energy at its highest point of the gait cycle. Our work shows that PAD patients have significantly 5 
decreased knee joint power generation (K2) due to the reduced concentric contraction of the knee 6 
extensors.  7 
Decreased forward propulsion 8 
In late stance the body is propelled forward mainly by the action of the ankle 9 
plantarflexors. Functionally, these muscles contract concentrically and accelerate the leg and the 10 
trunk forward to initiate swing, while decelerating the downward motion of the trunk (i.e., 11 
providing forward progression and support)16. Our results in the PAD patients, demonstrate that 12 
power generation via concentric contractions of the ankle plantarflexor muscles in late stance 13 
(A2;Figure 2) is decreased in the “Pain Free” condition and worsens in the “Pain” condition. 14 
This hypothesis is supported by previous findings from our and other laboratories demonstrating 15 
that PAD patients have significantly decreased ankle plantarflexor torques10 and strength11, 17, 18.  16 
Potential Clinical Implications for the Observed Gait Abnormalities:  Our findings for 17 
the time-distance gait parameters provide definitive evidence of abnormal temporal and spatial 18 
parameters in patients with PAD and confirm the generally accepted thought that claudicating 19 
patients have an abnormal gait5, 10, 19. More importantly, our advanced analysis with joint torques 20 
and powers provides a much more detailed delineation of the gait disturbance than that 21 
documented with spatial and temporal parameters and clearly documents the inability of the 22 
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PAD patient to walk efficiently, which by definition leads to increased energy cost and earlier 1 
fatigue20, 21.  2 
When comparing the abnormalities of joint torques and powers in PAD to other 3 
conditions, our values are in line with those of healthy elderly and elderly patients with 4 
osteoarthritis8, 22, 23. In contrast to these two groups however, the gait biomechanics of PAD 5 
patients appear to be significantly worse than healthy elderly subjects and those patients with 6 
severe arthritis. Specifically our data demonstrate that from the first few steps they take and 7 
before they experience any muscle pain claudicants walk with 29% decrease (versus controls) of 8 
their ankle plantarflexor power compared to a 13% for elderly osteoarthritis patients. Arthritis 9 
patients compensate for the 13% decrease in the power of their ankle plantarflexors by increasing 10 
the power of their knee and hip extensors (by 13% and 28% respectively).  In marked contrast to 11 
the arthritic patients, claudicants demonstrate a drop of compensatory power in these muscle 12 
groups by 38 and 21% respectively23. It is clear from a biomechanical standpoint that 13 
claudication produces a worse functional limitation than osteoarthritis. Our data support the 14 
findings that claudicating patients typically gather around the extreme low end of the physical 15 
activity spectrum24 and experience a severe decline in all domains of physical function17, 25.  16 
Potential Mechanisms for the Observed Gait Abnormalities The present data demonstrate 17 
significant abnormalities in the gait of claudicants that are present at the initiation of ambulation 18 
and prior to onset of pain. These baseline biomechanical impairments likely reflect a muscle 19 
metabolic myopathy and an axonal polyneuropathy in the lower extremities of patients with 20 
PAD26-28. Specifically, a number of reports have documented a metabolic myopathy in the PAD 21 
muscle that is related to defective mitochondrial bioenergetics and oxidative damage to skeletal 22 
muscle structures and components28-32. Furthermore, there is accumulating evidence suggesting 23 
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that chronic ischemia in patients with PAD results in a consistent pattern of electrodiagnostic 1 
abnormalities indicating axonal nerve loss28, 33. Our data further demonstrate that the baseline 2 
impairments worsen after the onset of claudication. This likely reflects exercise induced 3 
ischemia producing progressively worsening ischemic muscle pain and restriction of the lower 4 
extremity bioenergetics. The end result is a baseline metabolic neuromyopathy exacerbated by 5 
increased workload and ischemia.  Figure 4 illustrates a proposed pathway linking these basic 6 
pathophysiologic mechanisms with the specific biomechanic deficits identified in this work. The 7 
role played by each one of these mechanisms (blood flow, myopathy, neuropathy) and the way 8 
they are related to the clinical biomechanical findings of leg dysfunction should be the focus of 9 
intense future investigation and may hold the key to understanding PAD pathophysiology. 10 
INSERT FIGURE 4 ABOUT HERE  11 
On a clinical level, only recently have studies with large sample sizes (N= 700-2000) 12 
been able to demonstrate the long held assumption that claudicating patients have significantly 13 
reduced muscle strength 17, 34.  Our study utilizing advanced biomechanical analysis has allowed 14 
us to confirm these large scale studies with a limited number of patients and to implicate the site 15 
of the muscular deficit. Advanced biomechanical techniques thus provide a new avenue for 16 
evaluation, treatment, and rehabilitation of the PAD patient.  17 
Conclusions 18 
Biomechanical analysis using joint torques and powers demonstrates significant 19 
abnormalities in the gait of claudicating patients with bilateral PAD. These abnormalities are 20 
present at the onset of ambulation and worsen with the pain of claudication. Our work points to a 21 
failure of major muscle groups to optimally perform the sequence of functions (weight 22 
acceptance, transfer and propulsion) that characterize normal gait. The muscle groups most 23 
14 
 
affected by the chronic ischemia are the hip extensors, knee extensors and ankle dorsi- and 1 
plantar flexors. These findings introduce new insights into the pathophysiology of claudicating 2 
gait.  In the future these advanced biomechanical techniques will provide for detailed objective 3 
and quantitative evaluation of the gait deficit of the claudicating patient, allowing for evaluation 4 
of new treatment and rehabilitation strategies.  5 
6 
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Table 1 
Baseline characteristics of Peripheral Arterial Disease (PAD) patients and healthy controls. 
Clinical characteristics PAD (N=40 Limbs) Control (N=22 Limbs) 
Gender (male/female) 19/1 10/1 
Age (years) 64.25±9.01 66.27±9.22 
Body mass (kg) 79.52±13.83 77.89±10.65 
Body height (m) 1.72±0.04 1.74±0.08 
Disease duration (years) 6.05±3.84 0 
ABI <0.9 >0.9 
Right limb 0.55±0.22 1.1±0.11 
Left limb 0.50±0.23 1.1±0.09 
Smokers, n (%) 14 (70) 0 (0) 
Hypertension, n (%) 19 (95) 1 (9.09) 
Diabetes mellitus, n (%) 4 (20) 0 (0) 
Hyperlipidemia, n (%) 16 (80) 0 (0) 
BMI 26.82±4.66 25.60±2.94 
Note: ABI = ankle brachial index; BMI = body mass index  
Table  1
Table 2 
Group means and standard deviations for the time–distance gait measurements for Peripheral 
Arterial Disease (PAD) and control groups. PAD-PF= “Pain Free” and PAD-P= “Pain” 
conditions 
  Control (N=22 limbs) PAD (N= 40 limbs) 
    PAD-PF PAD-P 
Gait velocity (m/s) 1.37±0.15 1.04±0.14a,c 1.02±0.13b 
Stride length (m)  1.51±0.10 1.27±0.11a,c 1.22±0.09b 
Cadence (Steps/min) 110.09±9.09 99.15±8.51c 100.68±8.79b 
Step length (m)  0.68±0.05 0.62±0.07a,c 0.58±0.05b 
Step width (m) 0.13±0.03 0.14±0.03 0.15±0.05 
Stance phase (% of gait 
cycle) 
62.75±2.11 63.38±3.70 63.42±4.60 
Swing phase (% of gait 
cycle) 
37.25±2.11 36.62±3.70 36.58±3.83 
Double support (% of 
gait cycle)  
12.41±1.75 13.20±1.76a 15.14±4.23b 
Note:  ap<0.05, significant differences between PAD-PF and control.  
bp<0.05, significant differences between PAD-P and control.  
cp<0.05, significant differences between PAD-PF and PAD-P 
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Table 3 
Group means and standard deviations for joint torques of the ankle, knee and hip joint for 
Peripheral Arterial Disease (PAD) and control groups. PAD-PF= “Pain Free” and PAD-P= 
“Pain” conditions. The units for all values are N*m/kg. 
 Control (N=22 limbs) PAD (N=40 limbs)  
  PAD-PF PAD-P 
ADT -0.317±0.087 -0.279±0.086 -0.287±0.094 
APT 1.432±0.106 1.339±0.116a 1.246±0.199b 
KET 0.858±0.161 0.654±0.281a,c 0.704±0.219b 
KFT -0.154±0.082 -0.115±0.149 -0.102±0.161 
HET 0.841±0.159 0.738±0.148c 0.759±0.120b 
HFT -0.979±0.213 -0.893±0.147 -0.897±0.200 
ADT ankle dorsi flexor torque in early stance, APT ankle plantar flexor torque in late 
stance, KET knee extensor torque in early stance, KFT knee flexor torque in late stance, 
HET hip extensor torque in early stance, HFT hip flexor torque in late stance.   
Note:  ap<0.05, significant differences between PAD-PF and control.  
bp<0.05, significant differences between PAD-P and control.  
cp<0.05, significant differences between PAD-PF and PAD-P 
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Table 4 
Group means and standard deviations for joint powers of the ankle, knee and hip joint for 
Peripheral Arterial Disease (PAD) and control groups. PAD-PF = “Pain free” and PAD-P = 
“Pain” conditions. The units for all values are Watts/kg. 
 Control (N=22 limbs) PAD (N=40 limbs)  
  PAD-PF PAD-P 
A1 -0.344±0.063 -0.226±0.103a,b -0.182±0.107b 
A2 -0.484±0.223 -0.550±0.181 -0.539±0.326 
A3 3.944±0.959 3.240±1.068a,b 2.810±0.705b 
K1 -0.698±0.220 -0.433±0.263a,b -0.508±0.240b 
K2 0.587±0.250 0.323±0.257a,c 0.404±0.211b 
K3 -0.726±0.230 -0.692±0.336 -0.698±0.295 
H1 0.416±0.196 0.327±0.120c 0.314±0.132b 
H2 -0.776±0.235 -0.584±0.253 -0.605±0.249 
H3 0.759±0.293 0.735±0.272 0.745±0.268 
A1 ankle power absorption in early stance, A2 ankle power absorption in mid stance 
A3 ankle power generation in late stance, K1 knee power absorption in early stance, K2 
knee power generation in early mid-stance, K3 knee power absorption in late stance, 
H1 hip power generation in early stance, H2 hip power absorption in mid-stance, H3 
hip power generation in late stance   
Note:  ap<0.05, significant differences between PAD-PF and control.  
bp<0.05, significant differences between PAD-P and control.  
cp<0.05, significant differences between PAD-PF and PAD-P 
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FIGURE LEGENDS 
Figure 1. An illustration of the three phases of walking with the dominant flexor and 
extensor muscle groups that are involved in each phase based on the joint torques generated. The 
dominant muscle groups are identified in black if they contract concentrically (muscle shortens 
as it contracts) and in grey if they contract eccentrically (muscle lengthens as it contracts).  
A) Weight acceptance phase. It is also known as early stance, initial contact and heel 
strike phase and lasts from ipsilateral heel strike to contralateral toe off thus covering the first 
double support phase (initial 20% of stance). The right leg is accepting most of the weight of the 
body as it descents from previously being in single support on the left leg. In this phase the right 
hip extensors concentrically contract to extend the hip (reflected in the HET torque and H1 
power in Figures 2 and 3), the knee extensors eccentrically contract to allow the knee to bend 
(reflected in the KET torque and K1 power in Figures 2 and 3) and the ankle dorsiflexors 
eccentrically contract to maintain the ankle dorsi-flexed (reflected in the ADT torque and A1 
power in Figures 2 and 3). 
B) Single limb support phase. It is also known as the mid-stance phase and lasts from 
contralateral (here left) toe off until contralateral heel strike. During single support the body is at 
its highest point and over the extended ipsilateral leg. The body has maximum potential energy 
getting ready to fall forward for the next double support. Limited muscular contractions are 
needed during this phase except its early part where the knee extensors contract concentrically to 
extend the knee and straighten the leg (reflected in the KET torque and K2 power in Figures 2 
and 3). 
C) Propulsion phase. It is also known as the late stance or toe-off phase and lasts from 
contralateral heel strike to ipsilateral toe off. It is the last 20% of stance and it is the second 
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double support phase. In this phase the body is propelled forward onto the extended left leg 
mainly by the action of the right ankle plantarflexors (posterior calf compartments muscles, the 
most important of which are the gastrocnemius and soleus). Functionally, these muscles contract 
concentrically (reflected in the APT torque and A3 power in Figures 2 and 3) and accelerate the 
leg and the trunk forward and upward over the left leg (i.e., providing forward progression and 
weight support.  
Figure 2. The ensemble-average joint torque curves for the Peripheral Arterial Disease (PAD) 
patients (“Pain Free” PAD-PF and “Pain” conditions PAD-P; N=40 limbs) and the healthy 
controls (N=22 limbs) during the stance phase for the (a) ankle, (b) knee, and (c) hip joints. Note:  
ADT=ankle dorsiflexor torque in early stance, APT=ankle plantarflexor torque in late stance, 
KET=knee extensor torque in early stance, KFT=knee flexor torque in late stance, HET=hip 
extensor torque in early stance, and HFT=hip flexor torque in late stance.  Torques are 
normalized to body mass. A positive (+) value indicates extensor torque, and a negative (-) value 
indicates flexor torque.  
ap<0.05, significant differences between PAD-PF and control.  
bp<0.05, significant differences between PAD-P and control.  
cp<0.05, significant differences between PAD-PF and PAD-P. 
Figure 3. The ensemble-average joint power curves for the Peripheral Arterial Disease (PAD) 
patients (“Pain free” PAD-PF and “Pain” conditions PAD-P; N = 40 limbs) and the healthy 
controls (N = 22 limbs) during the stance phase for the (a) ankle, (b) knee, and (c) hip joints. 
Note:  A1 is the ankle power absorption in early stance, A2 is the ankle power absorption in mid 
stance, A3 is the ankle power generation in late stance, K1 is the knee power absorption in early 
stance, K2 is the knee power generation in mid-stance, K3 is the knee power absorption in late 
stance, H1 is the hip power generation in early stance, H2 is the hip power absorption in mid-
stance, H3 is the hip power generation in late stance.   
A positive (+) value indicates power generation (concentric contraction), and a negative (-) value 
indicates power absorption (eccentric contraction). Powers are normalized to body mass. 
ap<0.05, significant differences between PAD-PF and control.  
bp<0.05, significant differences between PAD-P and control.  
cp<0.05, significant differences between PAD-PF and PAD-P. 
Figure 4. Proposed pathway for the pathogenesis of gait impairment in patients with Peripheral 
Arterial Disease (PAD). The fundamental problem in claudicating patients is the presence of 
atherosclerotic blockages in the arteries supplying their legs. At rest, claudicating patients have 
adequate leg perfusion and experience no symptoms. During walking, however, the increased 
metabolic needs of the limb cannot be met and as the exercise continues the limb becomes 
progressively ischemic and painful, eventually forcing the patient to stop and rest. During rest, 
the metabolic demands of the limb return to baseline and the leg is reperfused. Repeated cycles 
of ischemia/reperfusion, occurring with basic daily activities, as simple as walking, initiate a 
combination of oxidative damage and inflammation which eventually produces a myopathy and 
axonal polyneuropathy in the claudicating limbs. We propose that the gait impairments we have 
identified at baseline (in the first few steps taken and prior to the onset of muscle pain) reflect the 
effects of this myopathy and neuropathy in the function of the PAD limbs. Several of these 
biomechanic impairments get worse after onset of claudication symptoms when exercise induced 
ischemia and increasing workload produce progressively worsening ischemic muscle pain and 
restriction of the lower extremity bioenergetics. 
 
